Janssen Biotech discontinued development of Abelzeta Pharma’s C-CAR039, a CD20/CD19 bispecific CAR T therapy, and Abelzeta regained all rights to the asset. The discontinuation resets commercial and clinical ownership for a therapy that targets B-cell malignancies through a dual-antigen approach. For Abelzeta, the move opens the door to redeploying the program under renewed strategy for development and potentially new partnering. For the broader CAR-T landscape, the notice is a reminder that portfolio pruning can rapidly change the competitive map. Investors and clinicians will look to see whether Abelzeta pursues further trials, modifies development plans, or seeks another strategic partner.